Frost & Sullivan Independent Equity Research

RedHill Biopharma Ltd.: The acceleration of RHB-104 Phase III Study in Crohn’s disease increases company value and share price.

redhill

Company: RedHill Biopharma        

Sector: Pharmaceuticals

Report type: Immediate Report

Published on: October 15, 2017

RedHill research articles:

Close Menu
Font Resize